Arvinas Competitors and Similar CompaniesClear all

Arvinas's competitors and similar companies include Foghorn Therapeutics, Lyell and Agenus.
Arvinas
Arvinas
Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases.
Foghorn Therapeutics
Foghorn Therapeutics
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
Lyell
Lyell
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
Agenus
Agenus
Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer.
Founding Date
Founding Date
N/A
Founding Date
2016
Founding Date
2018
Founding Date
1994
Type
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New Haven, US HQ
Locations
Cambridge, US HQ
Cambridge, US
Locations
South San Francisco, US HQ
Bothell, US
Seattle, US
Locations
Lexington, US HQ
Cambridge, GB
Emeryville, US
Berkeley, US
Vacaville, US
Employees
Employees
13329% increase
Employees
16135% increase
Employees
188
Employees
38927% decrease
Valuation ($)
Valuation ($)
2.1 b
Valuation ($)
369 m
Valuation ($)
397.7 m
Valuation ($)
125.8 m
Twitter followers
Twitter followers
3.1 k
Twitter followers
1.1 k
Twitter followers
N/A
Twitter followers
2.5 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
13
Number of tweets (last 30 days)
9
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
8
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
2
Average likes per tweet (last 30 days)
2.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
13.4
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
84.62%
Percentage of tweets with engagement (last 30 days)
88.89%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%

Financial

Revenue (est.)
Revenue (est.)
$78.5m (FY, 2023)
Revenue (est.)
$34.2m (FY, 2023)
Revenue (est.)
$130k (FY, 2023)
Revenue (est.)
$156.3m (FY, 2023)
Net income
Net income
($367.3m) (FY, 2023)
Net income
($98.4m) (FY, 2023)
Net income
($234.6m) (FY, 2023)
Net income
($257.4m) (FY, 2023)

Funding

Total funding raised
Total funding raised
$ 111.6m
Total funding raised
$ 50m
Total funding raised
N/A
Total funding raised
$ 171.1m
For sources of this data, please see the company profile

View Company Profiles

Foghorn Therapeutics
HQ
Cambridge, US
Employees
161↑ 35% increase

Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.

View company
Lyell
HQ
South San Francisco, US
Employees
188

Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.

View company
Agenus
HQ
Lexington, US
Employees
389↓ 27% decrease

Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer.

View company